SLDB Form 144: Insider sale notice for RSU settlement

Solid Biosciences filed a Form 144 reporting a proposed sale of Common Stock tied to the settlement of vested restricted stock units on 02/18/2026.

Rhea-AI Filing Summary

Solid Biosciences filed a Form 144 reporting a proposed sale of Common Stock tied to the settlement of vested restricted stock units on 02/18/2026. The filing lists proposed/settled share movements including examples of prior sales by a selling holder, including Brooks Gabriel: 28,335 shares and 12,616 shares.

The notice ties the 02/18/2026 entry to compensation (RSU settlement); proceeds and specific distribution methods are shown for prior sales in the excerpt.

Insights

Securities Compliance Counsel

Form 144 notifies the market of proposed sale of Common Stock from RSU settlement.

The filing records a 02/18/2026 settlement of vested restricted stock units classified as compensation. The excerpt also shows prior reported sales by a holder: 28,335 shares for $182,389.56 and 12,616 shares for $81,267.65.

Regulatory effect is procedural: Form 144 provides required notice for Rule 144 distributions. Cash‑flow treatment and final sale timing are governed by selling holder actions and are not detailed in the provided excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does SLDB's Form 144 report?

The filing reports a proposed sale of Common Stock tied to an RSU settlement on 02/18/2026. It includes prior sale entries with concrete share and dollar amounts for a selling holder.

Who is listed as a selling holder in the SLDB excerpt?

The excerpt lists Brooks Gabriel as a selling holder with prior sales of 28,335 shares and 12,616 shares, showing proceeds of $182,389.56 and $81,267.65.

Does the Form 144 show the reason for the sale at SLDB?

Yes. The 02/18/2026 entry is described as settlement of vested restricted stock units treated as compensation. Other entries are dated earlier and are recording prior sales.

Are sale proceeds or distribution methods specified for the 02/18/2026 entry?

The excerpt links the 02/18/2026 entry to compensation (RSU settlement) but does not list explicit proceeds or detailed distribution methods for that specific entry in the provided text.

Does this Form 144 change ownership percentages for SLDB?

The excerpt does not state post‑transaction ownership percentages or shares outstanding, so no change to ownership percentages is reported in the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 09:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001997809
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Solid Biosciences Inc.
SEC File Number	001-38360
Address of Issuer	500 Rutherford Avenue Charlestown MASSACHUSETTS 02129
Phone	(617)-337-4680
Name of Person for Whose Account the Securities are To Be Sold	Brooks Gabriel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	5563	32395.02	83412695	02/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/18/2026	Settlement of vested restricted stock units	Issuer			5563	02/18/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brooks Gabriel C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	02/02/2026	28335	182389.56
Charlestown C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	02/04/2026	12616	81267.65

144: Remarks and Signature

Remarks	The sale reported on this Form 144 was made to cover witholding taxes following the vesting of previously granted performance stock units pursuant to a durable sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-cover-election. The sale does not represent a discretionary trade by Dr. Brooks.
Date of Notice	02/18/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/15/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)